You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Suppliers and packagers for generic pharmaceutical drug: QUETIAPINE FUMARATE


✉ Email this page to a colleague

« Back to Dashboard


QUETIAPINE FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Accord Hlthcare QUETIAPINE FUMARATE quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 206252 ANDA Accord Healthcare Inc. 16729-132-12 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-132-12) 2017-11-30
Accord Hlthcare QUETIAPINE FUMARATE quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 206252 ANDA Bluepoint Laboratories 68001-511-06 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (68001-511-06) 2021-08-31
Accord Hlthcare QUETIAPINE FUMARATE quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 090681 ANDA Accord Healthcare Inc. 16729-095-12 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-095-12) 2019-01-01
Accord Hlthcare QUETIAPINE FUMARATE quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 090681 ANDA Accord Healthcare Inc. 16729-096-12 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-096-12) 2019-01-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Quetiapine Fumarate

Last updated: July 29, 2025

Introduction

Quetiapine fumarate is an atypical antipsychotic medication primarily used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Its widespread clinical adoption has driven global demand, prompting pharmaceutical companies to establish robust supply chains. As the market for quetiapine fumarate expands, understanding the key suppliers—from raw material producers to finished drug manufacturers—is vital for stakeholders aiming to secure reliable sourcing, ensure regulatory compliance, and optimize procurement strategies.

This article provides a comprehensive overview of the leading suppliers of quetiapine fumarate, highlighting their production capabilities, geographic presence, quality standards, and market influence.

Raw Material Suppliers for Quetiapine Fumarate

1. Chemical Intermediates Manufacturers

The synthesis of quetiapine fumarate involves complex chemical intermediates and active pharmaceutical ingredients (APIs). Producers of these raw materials are critical players in the supply chain and often operate under stringent quality and regulatory standards.

  • Zhejiang Hisun Pharmaceutical Co., Ltd. (China): A prominent manufacturer of active pharmaceutical ingredients, including intermediates for antipsychotic drugs. Their capabilities encompass both bulk chemical synthesis and custom manufacturing, supported by ISO and GMP certifications (source: [1]).

  • Jubilant Life Sciences (India): Specializes in the synthesis of chemical intermediates and APIs used in neuropsychiatric medications. Their large-scale facilities enable consistent supply for global markets.

  • Therapeutics Unlimited, Inc. (USA): Focused on specialty chemical intermediates, particularly for central nervous system (CNS) drugs. They supply high-purity intermediates to pharmaceutical manufacturers worldwide.

2. API Manufacturers Producing Quetiapine Fumarate

The API constitutes the core component of the final pharmaceutical product. Manufacturers in this segment are critical for ensuring quality, purity, and compliance.

  • Hetero Labs Limited (India): One of the world's leading API producers, supplying quetiapine fumarate with GMP certification. Their facilities serve clients globally and possess extensive regulatory approvals.

  • Mingke Pharmaceutical (China): An emerging supplier with capacity for large-scale API manufacturing under international quality standards, including WHO-GMP.

  • Dr. Reddy’s Laboratories (India): Besides manufacturing finished formulations, they also produce APIs for antipsychotic drugs, including quetiapine fumarate.

3. Contract Manufacturing Organizations (CMOs)

CMOs play a vital role in scaling production and meeting market demands.

  • Aenova Group (Germany): Offers both API production and formulation services, with a focus on CNS drugs, including quetiapine fumarate.

  • Catalent Pharma Solutions (USA): Provides comprehensive manufacturing services, including licensed API supply and pharmaceutical formulation.

  • Biocon (India): Known for producing high-quality APIs and collaborating with pharmaceutical companies for large-volume requirements.

Finished Formulation and Commercial Suppliers

While raw materials and APIs are vital, the final drug products reaching consumers come from finished formulation manufacturers.

  • Pfizer Inc.: Historically associated with quetiapine fumarate formulations; may act as a supplier or licensee depending on market specifics.

  • Teva Pharmaceutical Industries (Israel): Manufactures generic quetiapine fumarate tablets and capsules, distributing globally.

  • Mylan (now part of Viatris): Supplies generic versions of quetiapine fumarate, with extensive manufacturing and distribution networks.

  • Sandoz (Novartis): A key player in producing biosimilar and branded generics, including formulations of quetiapine fumarate.

Geographical Distribution of Suppliers

The supply chain for quetiapine fumarate is global, with prominent manufacturing hubs located in India, China, Europe, and the United States.

  • India and China: Dominate API and intermediate production, leveraging cost advantages and increasing capacities. Major players such as Hetero Labs, Mingke, and Jubilant contribute significantly to global supply.

  • Europe and the USA: Focus on quality assurance, regulatory compliance, and formulation manufacturing, hosting companies like Aenova, Catalent, and Pfizer.

Regulatory and Quality Considerations

Suppliers of quetiapine fumarate must adhere to strict international standards, including GMP, ISO, FDA, and EMA regulations. Certifications provide assurance of purity, stability, and process consistency essential for patient safety and regulatory approvals.

Given the complex synthesis and potential for impurities, dependable suppliers invest heavily in quality management systems, process validation, and compliance audits.

Market Dynamics and Supplier Selection Criteria

  • Capacity and Scalability: Suppliers must meet current and projected demand.
  • Quality Standards: GMP certification and validated manufacturing processes.
  • Regulatory Track Record: Proven compliance with global agencies (FDA, EMA, PMDA).
  • Cost Efficiency: Competitive pricing often favors suppliers from India and China.
  • Lead Times and Reliability: Consistent delivery schedules are critical to avoid supply disruptions.

Emerging Trends and Challenges

  • Supply Chain Volatility: Political tensions, trade policies, and regulatory hurdles, especially involving China and India, impact raw material availability.
  • Quality Concerns: Incidents related to substandard APIs emphasize the importance of thorough supplier due diligence.
  • Sustainability and Responsible Manufacturing: Increasing focus on environmental impact and ethical sourcing influences supplier evaluation.

Conclusion

The supply chain for quetiapine fumarate encompasses a diverse array of manufacturers, primarily clustered in India and China for raw materials and APIs, with developed markets like Europe and the USA focused on formulation, quality assurance, and distribution. Selecting the right suppliers involves balancing capacity, compliance, quality, cost, and reliability—factors critical to maintaining uninterrupted supply and regulatory compliance.

Key Takeaways

  • Leading API suppliers such as Hetero Labs, Mingke, and Jubilant are essential for global production of quetiapine fumarate.
  • Raw material and API production are predominantly concentrated in India and China, benefiting from cost efficiencies.
  • Finished formulations are supplied worldwide by pharmaceutical giants like Teva, Viatris, and Sandoz.
  • Continuous due diligence, regulatory compliance, and quality assurance are paramount in supplier selection.
  • Emerging geopolitical and regulatory trends necessitate diversification and resilience planning within the supply chain.

FAQs

1. Who are the primary API producers of quetiapine fumarate?
Major API producers include Hetero Labs (India), Mingke Pharmaceutical (China), and Dr. Reddy’s Laboratories (India), all operating under GMP standards.

2. What regions dominate the supply chain for quetiapine fumarate?
India and China dominate API and raw material manufacturing, while Europe and the USA focus on formulation manufacturing and distribution.

3. Are there regulatory concerns associated with suppliers of quetiapine fumarate?
Yes, ensuring suppliers have GMP certification, proper documentation, and regulatory approvals (FDA, EMA) is essential to mitigate quality and compliance risks.

4. How does supply chain diversification impact the procurement of quetiapine fumarate?
Diversification reduces dependency on a single source, mitigates risks of disruption due to geopolitical or regulatory issues, and enhances supply resilience.

5. What factors should pharmaceutical companies consider when selecting a supplier for quetiapine fumarate?
Capacity, quality standards, regulatory compliance, cost, lead times, reliability, and sustainability practices are critical considerations.


Sources
[1] Zhejiang Hisun Pharmaceutical Co., Ltd. Corporate Website.
[2] Jubilant Life Sciences Annual Report.
[3] Hetero Labs Ltd. API Product Portfolio.
[4] Mylan (Viatris) API Supply Chain Overview.
[5] European and US-based formulation manufacturers certifications.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.